Small molecules for bone diseases

Area of Science:

• Pharmacology
• Biochemistry
• Orthopedics

Background:

• Bone diseases affect over 100 million globally, including osteoporosis, osteoarthritis, and inflammatory arthritis.
• Osteoporosis, a major bone disease, lacks early symptoms and significantly increases fracture risk.
• Current treatment options for bone diseases remain insufficient, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

• To review low molecular mass modulators targeting bone diseases disclosed in recent patent applications and scientific literature.
• To provide an overview of historical, emerging, and re-visited therapeutic targets for bone diseases.
• To identify current research trends and key industry players in bone disease drug discovery.

Main Methods:

• Systematic review of patent applications and scientific articles.
• Focus on low molecular mass modulators of bone disease targets.
• Analysis of research published primarily within the last five years.

Main Results:

• Identification of various low molecular mass modulators for both established and novel bone disease targets.
• Overview of emerging therapeutic targets and re-validated historical targets.
• Insight into the current landscape of bone disease research and major contributing entities.

Conclusions:

• Significant progress has been made in drug discovery for bone diseases.
• Research focus has shifted from traditional targets to newly validated or re-visited ones.
• Cathepsin K inhibitors represent a promising therapeutic class nearing market approval for bone disease treatment.